APAC PRODUCT
Aplagon is developing APACs, biological mimetics of heparin proteoglycan, as potent, first-in-class antithrombotic products for the clinical management of both the short- and long- term complications of vascular intervention-related blood vessel occlusions. APACs also carry a lower bleeding risk than typical systemically acting antithrombotics.
APAC MULTIPLE MECHANISMS OF ACTION
APACs have a number of important and unique properties that include dual antiplatelet (AP) and anticoagulant (AC) modes of action, as well as the ability to target and act locally at the vascular injury site. In addition, they also beneficially influence vascular smooth muscle cells.
OUR COMPANY
Aplagon was established to translate proprietary scientific discoveries on APACs from the laboratory into the clinic. The Company is supported by an experienced management team and Board, an excellent scientific network, and backed by a strong syndicate of leading Finnish investors.
